OncoSeq
OncoSeq: an innovative single-cell system for immunomonitoring
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0OncoSeq project word cloud
Explore the words cloud of the OncoSeq project. It provides you a very rough idea of what is the project "OncoSeq" about.
Project "OncoSeq" data sheet
The following table provides information about the project.
| Coordinator |
PARMENIDES STIFTUNG
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2017-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-11-01 to 2018-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PARMENIDES STIFTUNG | DE (MUNCHEN) | coordinator | 41˙250.00 |
| 2 | ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS | FR (PARIS) | participant | 108˙750.00 |
Map
Project objective
Host immunity plays a central and complex role in tumour progression, and the quality and quantity of immune infiltrate at the tumour site is used as a prognostic marker of cancer progression. Therefore, detailed single-cell analysis of tumor infiltrating immune cells, and ultimately liquid biopsy of circulating immune cells, is of vital importance for the development of new and improved immunotherapy strategies, and for diagnosis, prognosis, patient stratification and follow-up. We propose in OncoSeq to adapt the droplet barcoding microfluidics system, an output from the ERC EVOEVO project, to develop a novel “molecular cytometer” for high-throughput transcriptomic and phenotypic analysis, at the single-cell level, of tumor infiltrating or circulating immune cells. Readout of genotype and phenotype will be entirely based on next generation sequencing (NGS) allowing higher phenotypic multiplexing capacity (100s of phenotypic markers) than fluorescence (Flow cytometry) or mass spectrometry (CyTOF) based approaches (≤40 markers) and simultaneous RNA-sequencing (RNA-seq), allowing the creation of high-resolution phenotype-transcriptome maps for tens of thousands of single cells. This will be a powerful tool for cancer prognosis, clinical decision making and monitoring of disease progression, especially in the context of immunotherapy. So far, no such diagnostic instruments, enabling high-throughput single-cell phenotypic and transcriptomic analysis, exist. The technology developed will be transferred to our industrial partner through licensing for internal development of novel immunotherapies. In addition, once the prototype system is fully validated, we plan, with our industrial partners, to create a new company specialising in the sale of instruments and associated consumables for clinical single-cell immuno-monitoring for the research and clinical oncology markets.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSEQ" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCOSEQ" are provided by the European Opendata Portal: CORDIS opendata.
